Abstract: Analysis of a breath sample is a noninvasive point-of-care tool with ever increasing screening and clinical applicability. Herein we describe a method to analyze the content of low-level, trace volatile organic compounds from alveolar breath captured as a breath sample from a patient suspected of having a disease related to coronavirus infection. The breath sample is then analyzed using a gas phase analysis methodology, such as gas chromatography-mass spectroscopy (“GCMS”), to generate an analysis result, such as a GCMS spectrum. A computer system is then used to develop a fingerprint pattern from the analysis result. The fingerprint pattern is then used to determine a patient status for the patient. The fingerprint pattern is typically a grouping of 75 to 450 compounds of known concentration which are indicative of a particular disease related to coronavirus.

Abstract: Analysis of a breath sample is a noninvasive point-of-care tool with ever increasing clinical applicability. Herein we describe a method to analyze the content of low-level, trace volatile organic compounds from alveolar breath captured as a breath sample from a patient suspected of having a fatty liver disease. The breath sample is then analyzed using a gas phase analysis methodology, such as gas chromatography-mass spectroscopy (“GCMS”), to generate an analysis result, such as a GCMS spectrum. A computer system is then used to develop a fingerprint pattern from the analysis result. The fingerprint pattern is then used to determine a patient status for the patient. The fingerprint pattern is typically a grouping of 75 to 450 compounds of known concentration which are indicative of a particular fatty liver disease.

Abstract: Analysis of a breath sample is a noninvasive point-of-care tool with ever increasing clinical applicability. Herein we describe a method to analyze the content of low-level, trace volatile organic compounds from alveolar breath captured as a breath sample from a patient. The breath sample is then analyzed using a gas phase analysis methodology, such as gas chromatography-mass spectroscopy (“GCMS”), to generate an analysis result, such as a GCMS spectrum. A computer system is then used to develop a fingerprint pattern from the analysis result. The fingerprint pattern is then used to determine a patient status for the patient. The fingerprint pattern is typically a grouping of 75 to 450 compounds of known concentration which are indicative of a particular neurodegenerative disease.

Abstract: The present invention describes systems and methods for providing portable environment monitoring systems. An exemplary embodiment of the present invention provides a portable environment monitoring system comprising a sensor enabled to sense an airborne analyte. The portable environment monitoring system also includes a microprocessor in communication with the sensor and enabled to process information received from the sensor. Additionally, the portable environment monitoring system includes a memory device in communication with the microprocessor and enabled to store information received from the microprocessor. Furthermore, a user is enabled to ambulate with the portable environment monitoring system.